Sesamin

Pharmacology & Research

Sesamin is the principal furofuran lignan of sesame seed and oil, also present in eleuthero and devil’s club. It is fat-soluble, tasteless and heat-stable, and its literature has two genuinely reproducible human threads. First, a modest lipid-lowering effect — small trials and their meta-analysis show reductions in total and LDL cholesterol ^{1Reference 12022Meta-analysisEffects of sesamin supplementation on obesity, blood pressure and lipid profile: a systematic review and meta-analysis of RCTsView study →}. Second, and most distinctive, a vitamin-E-sparing action: sesamin blocks the breakdown of tocopherols, raising blood γ-tocopherol — a real sesamin↔vitamin-E pharmacokinetic interaction ^{4,10Reference 4Parker RS et al. · 2000Cytochrome P450-3A-dependent metabolism of tocopherols and inhibition by sesaminView study →Reference 10Cooney RV et al. · 2001Effects of dietary sesame seeds on plasma tocopherol levelsView study →}. Two disambiguations matter throughout: sesamin is not sesamol (a roasting-derived antioxidant phenol) or sesamolin (a related lignan), and commercial “sesame lignan” supplements are typically a ~1:1 mix of sesamin and its epimer episesamin, which is how most trials were dosed ^{5Reference 52012Comparison of the metabolism of sesamin and episesamin by drug-metabolising enzymes in human liverView study →}.

1. Lipid-lowering

The best-supported human application, though modest. A meta-analysis of 7 RCTs (n≈212) found significant reductions in total cholesterol (−11 mg/dL) and LDL-C (−8 mg/dL), with no effect on HDL or triglycerides, mechanistically supported by PPAR-α upregulation and SREBP-1 downregulation ^{1Reference 12022Meta-analysisEffects of sesamin supplementation on obesity, blood pressure and lipid profile: a systematic review and meta-analysis of RCTsView study →}, and reinforced by LXRα-mediated suppression of lipogenesis ^{13Reference 132019Sesamin, a naturally occurring lignan, inhibits ligand-induced lipogenesis through interaction with LXRα and PXRView study →}.

Gap: the trials are few, small and heterogeneous, several from lignan-supplement industry sources, and often used sesamin/episesamin mixtures rather than pure sesamin; the effect size is modest with no hard-outcome data ^{1Reference 12022Meta-analysisEffects of sesamin supplementation on obesity, blood pressure and lipid profile: a systematic review and meta-analysis of RCTsView study →}.

2. Antioxidant / vitamin-E-sparing

Sesamin’s most reproducible human effect is really a drug-nutrient interaction: dietary sesame lignans raise plasma γ-tocopherol (and tissue α-tocopherol) by blocking tocopherol side-chain catabolism ^{4,10,9Reference 4Parker RS et al. · 2000Cytochrome P450-3A-dependent metabolism of tocopherols and inhibition by sesaminView study →Reference 10Cooney RV et al. · 2001Effects of dietary sesame seeds on plasma tocopherol levelsView study →Reference 92005Beyond vitamin-E supplementation: an alternative strategy to improve vitamin-E statusView study →}. A small combination RCT of sesame lignans plus vitamin E reported improved antioxidant capacity and subjective fatigue ^{11Reference 112015Sesame lignans and vitamin E supplementation improve subjective status and antioxidative capacity in healthy humans with daily fatigueView study →}.

Gap: the “benefit” is a biomarker shift (raised γ-tocopherol and antioxidant capacity), not a hard clinical endpoint, and the fatigue trial was subjective and industry-run ^{11Reference 112015Sesame lignans and vitamin E supplementation improve subjective status and antioxidative capacity in healthy humans with daily fatigueView study →}.

3. Blood pressure

A 4-week double-blind crossover trial (n=25 mildly hypertensive, 60 mg/day) reported a significant blood-pressure reduction ^{2Reference 22009Antihypertensive effects of sesamin in humansView study →}, and the meta-analysis found a systolic drop (~−3.7 mmHg) with no diastolic effect ^{1Reference 12022Meta-analysisEffects of sesamin supplementation on obesity, blood pressure and lipid profile: a systematic review and meta-analysis of RCTsView study →}.

Gap: very small numbers, a modest systolic-only effect, and mixed results across trials — not established therapy ^{2Reference 22009Antihypertensive effects of sesamin in humansView study →}.

4. Hepatoprotective (NAFLD)

Sesamin antagonises LXRα (and interacts with PXR) to suppress lipogenesis, reducing hepatic steatosis and inflammation in animal models ^{13Reference 132019Sesamin, a naturally occurring lignan, inhibits ligand-induced lipogenesis through interaction with LXRα and PXRView study →}.

Gap: entirely cell and animal — no human NAFLD trial of sesamin exists ^{13Reference 132019Sesamin, a naturally occurring lignan, inhibits ligand-induced lipogenesis through interaction with LXRα and PXRView study →}.

5. Anti-inflammatory

Sesame lignans downregulate platelet-activating-factor acetylhydrolase and reduce LDL oxidative susceptibility, with broad preclinical anti-inflammatory signals ^{8Reference 82020ReviewSesame lignans reduce LDL oxidative susceptibility by downregulating platelet-activating-factor acetylhydrolaseView study →}; sesamin also non-competitively inhibits Δ5-desaturase, shifting the n-6/n-3 fatty-acid balance in a way that plausibly tempers eicosanoid-driven inflammation ^{3,7Reference 3Shimizu S et al. · 1991Sesamin is a potent and specific inhibitor of Δ5-desaturase in polyunsaturated-fatty-acid biosynthesisView study →Reference 71995AnimalInteraction of sesamin and eicosapentaenoic acid against Δ5-desaturation and the n-6/n-3 ratio of essential fatty acids in ratView study →}.

Gap: no dedicated human anti-inflammatory outcome trial for isolated sesamin ^{8Reference 82020ReviewSesame lignans reduce LDL oxidative susceptibility by downregulating platelet-activating-factor acetylhydrolaseView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Δ5-desaturase (fatty-acid biosynthesis)	non-competitive inhibition; shifts n-6/n-3 balance	anti-inflammatory / lipid rationale
CYP3A / tocopherol-ω-hydroxylase	inhibits tocopherol catabolism → ↑ γ-tocopherol	antioxidant / vitamin-E-sparing (load-bearing)
PPAR-α ↑; SREBP-1, ACC, FAS ↓	↓ lipogenic enzymes, ↑ fatty-acid oxidation	lipid-lowering
LXRα antagonism / PXR	↓ ligand-induced hepatic lipogenesis	anti-fatty-liver (preclinical)
PAF-acetylhydrolase ↓	↓ LDL oxidative susceptibility	antioxidant / anti-atherogenic

Pharmacokinetics

Oral sesamin (usually as a ~1:1 sesamin/episesamin mix) peaks in plasma around 5 hours, reaching steady state by day 7 with once-daily dosing and no accumulation over 28 days ^{12Reference 122013Pharmacokinetics and safety of the sesame lignans sesamin and episesamin in healthy subjectsView study →}. It is extensively metabolised in the liver by CYP450 (chiefly CYP2C9 and CYP1A2) to mono- and di-catechol metabolites, then glucuronidated and O-methylated — and the routing differs measurably between sesamin and episesamin, giving different metabolite profiles ^{5,6Reference 52012Comparison of the metabolism of sesamin and episesamin by drug-metabolising enzymes in human liverView study →Reference 62012AnimalIdentification of the metabolites of episesamin in rat bile and human liver microsomesView study →}. Those catechol metabolites are themselves potent antioxidants and circulate in human plasma ^{12Reference 122013Pharmacokinetics and safety of the sesame lignans sesamin and episesamin in healthy subjectsView study →}. Note that episesamin is chiefly a processing/refining epimer of dietary sesame rather than a major in-vivo conversion product — supplements dose it directly. The load-bearing interaction is the tocopherol one: by inhibiting CYP3A-dependent tocopherol catabolism, sesamin lengthens tocopherol residence and raises plasma γ-tocopherol ^{4Reference 4Parker RS et al. · 2000Cytochrome P450-3A-dependent metabolism of tocopherols and inhibition by sesaminView study →}.

Clinical trials

Human data are real but thin, and centre on lipids and blood pressure: a 2022 meta-analysis of 7 RCTs (n≈212) showing modest reductions in total cholesterol, LDL and systolic BP with no effect on HDL, triglycerides, diastolic BP or weight ^{1Reference 12022Meta-analysisEffects of sesamin supplementation on obesity, blood pressure and lipid profile: a systematic review and meta-analysis of RCTsView study →}, plus a standalone BP crossover trial ^{2Reference 22009Antihypertensive effects of sesamin in humansView study →}. The vitamin-E kinetics are demonstrated in small feeding studies ^{10Reference 10Cooney RV et al. · 2001Effects of dietary sesame seeds on plasma tocopherol levelsView study →} and a combination fatigue RCT ^{11Reference 112015Sesame lignans and vitamin E supplementation improve subjective status and antioxidative capacity in healthy humans with daily fatigueView study →}, and a Phase-I study established tolerability of 50 mg/day for 28 days ^{12Reference 122013Pharmacokinetics and safety of the sesame lignans sesamin and episesamin in healthy subjectsView study →}. There are no human trials for NAFLD, dedicated anti-inflammatory endpoints or ergogenic outcomes — those are preclinical, and several human trials are small, mixture-based and industry-sponsored.

Last checked: July 2026.

Toxicity & Safety

Sesamin is a low-toxicity dietary lignan with a long history of consumption in sesame, and Phase-I dosing of 50 mg/day of sesame lignans for 28 days produced no serious adverse events ^{12Reference 122013Pharmacokinetics and safety of the sesame lignans sesamin and episesamin in healthy subjectsView study →}. One clarification prevents a common misfiling: sesame is a major, sometimes anaphylactic, food allergen — but the allergens are seed storage proteins, not the lignan sesamin; purified sesamin is not a recognised allergen, though a botanically-sourced extract could in principle carry trace seed protein. The defining interaction is the vitamin-E one — sesamin raises γ-tocopherol by inhibiting tocopherol catabolism ^{4Reference 4Parker RS et al. · 2000Cytochrome P450-3A-dependent metabolism of tocopherols and inhibition by sesaminView study →}; its own CYP2C9/CYP1A2/CYP3A involvement suggests a theoretical potential to affect co-metabolised drugs ^{5Reference 52012Comparison of the metabolism of sesamin and episesamin by drug-metabolising enzymes in human liverView study →}, and additive effects with antihypertensive or lipid-lowering agents are plausible but unstudied.

Pregnancy & lactation

Dietary sesame fine; avoid concentrated supplements. Culinary sesame is customary and not a specific concern, but no safety studies support isolated or high-dose sesamin in pregnancy or lactation, so concentrated supplements are best avoided.

Dosage

There is no established therapeutic dose, and nothing here is a recommendation. Human trials used 50 mg/day of sesame lignans (1:1 sesamin/episesamin) for 28 days (pharmacokinetics/safety) ^{12Reference 122013Pharmacokinetics and safety of the sesame lignans sesamin and episesamin in healthy subjectsView study →}, 60 mg/day of sesamin for 4 weeks (blood pressure) ^{2Reference 22009Antihypertensive effects of sesamin in humansView study →}, and a 10 mg lignan plus vitamin-E combination (fatigue) ^{11Reference 112015Sesame lignans and vitamin E supplementation improve subjective status and antioxidative capacity in healthy humans with daily fatigueView study →}; typical supplements provide 50–100 mg/day of “sesame lignans.” The tocopherol-sparing biomarker effect appears at very low intakes ^{10Reference 10Cooney RV et al. · 2001Effects of dietary sesame seeds on plasma tocopherol levelsView study →}.

References